Rhenman & Partners Asset Management AB Sells 75,000 Shares of Dianthus Therapeutics, Inc. $DNTH

Rhenman & Partners Asset Management AB lowered its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 43.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 98,627 shares of the company’s stock after selling 75,000 shares during the period. Rhenman & Partners Asset Management AB owned 0.23% of Dianthus Therapeutics worth $4,064,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in DNTH. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $64,000. Tower Research Capital LLC TRC raised its position in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Dianthus Therapeutics in the 4th quarter worth approximately $135,000. Finally, Glenmede Investment Management LP bought a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $213,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Up 7.4%

Dianthus Therapeutics stock opened at $82.07 on Friday. The company has a market capitalization of $4.49 billion, a P/E ratio of -19.87 and a beta of 1.18. The stock’s 50 day moving average is $87.10 and its 200 day moving average is $65.07. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Activity at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 8,224 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the sale, the executive vice president owned 8,224 shares in the company, valued at $738,844.16. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 149,121 shares of company stock worth $12,635,454 in the last 90 days. 3.02% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Jefferies Financial Group set a $98.00 target price on Dianthus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 9th. Wells Fargo & Company assumed coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price target on the stock. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.